"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
- Patient Information:
Details with Side Effects
DOSAGE AND ADMINISTRATION
The recommended dosage for adult and pediatric patients 6 years of age and older is two inhalations four times a day at regular intervals, which provides a dose of 14 mg per day. In patients whose asthma is well controlled on this dosage (e.g., patients who only need occasional inhaled or oral beta2-agonists and who are not experiencing serious exacerbations), less frequent administration may be effective.
Each Tilade (nedocromil inhalation aerosol) Inhaler canister must be primed with 3 actuations prior to the first use. If a canister remains unused for more than 7 days, then it should be reprimed with 3 actuations. Tilade (nedocromil inhalation aerosol) Inhaler may be added to the patient's existing treatment regimen (e.g., bronchodilators). When a clinical response to Tilade (nedocromil inhalation aerosol) Inhaler is evident and if the patient's asthma is under good control, an attempt may be made to decrease concomitant medication usage gradually. Proper inhalational technique is essential (see Patient Instructions for Use). Patients should be advised that the optimal effect of Tilade (nedocromil inhalation aerosol) therapy depends upon its administration at regular intervals, even during symptom-free periods.
Tilade (nedocromil inhalation aerosol) Inhaler is available in 16.2 g canisters providing at least 104 metered inhalations. Each Tilade (nedocromil inhalation aerosol) canister contains 210 mg nedocromil sodium. Each pack is supplied with patient instructions, a tan-colored rubber valve cover, and white plastic mouthpiece and cover, bearing the Tilade (nedocromil inhalation aerosol) logo. The Tilade (nedocromil inhalation aerosol) mouthpiece should not be used with other aerosol medications and the Tilade (nedocromil inhalation aerosol) canister should not be used with other mouthpieces. Each actuation meters 2.00 mg nedocromil sodium from the valve and delivers 1.75 mg nedocromil sodium from the mouthpiece.
NDC 0585-0685-02 One 16.2 g Canister (104 Metered Inhalations)
The canister should be discarded after the labeled number of actuations have been used. The amount of medication in each actuation cannot be assured after this point.
Store between 2 to 30°C (36 to 86°F). Do not freeze. Avoid spraying in eyes. Contents under pressure. Do not puncture, incinerate, place near sources of heat, or use with other mouthpieces. Exposure to temperatures above 120°F may cause bursting. Never throw canister into fire or incinerator. Keep out of the reach of children. For best results, the canister should be at room temperature before use.
Shake well before using.
Note: The indented statement below is required by the Federal government's Clean Air Act for all products containing or manufactured with chlorofluorocarbons (CFCs).
A notice similar to the above WARNING has been placed in the "Patient Instructions for Use" portion of this package insert under the Environmental Protection Agency's (EPA's) regulations. The patient's warning states that the patient should consult his or her physician if there are questions about alternatives.
Distributed by: King Pharmaceuticals™, Inc. Bristol, TN 37620. Manufactured by: Aventis Pharma LTD, Holmes Chape,l Cheshire CW48B3, United Kingdom. FDA rev date:
Last reviewed on RxList: 7/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Tilade Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.